source
- FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell LymphomaThe FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.onclive · 2mo ago↗ source
- Takeda to target 4,500 jobs as incoming CEO continues restructuringTakeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring. About 4,500 roles will be affected, the company said Wednesday in ...Endpoints · 2mo ago↗ source
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive